Delta Diagnostics is receiving 200,000 euros from investment fund Uniiq. The Rotterdam-based technology provider for the detection and diagnosis of various diseases will use the money to further develop its diagnostics method. The TNO spinoff was founded in 2018 and is currently testing its equipment in collaboration with R&D partners.
Measuring biomarkers often requires lengthy and costly lab tests. By using optical chips and so-called ring resonators, Delta Diagnostics can measure these same biomarkers in minutes instead of days. For many diseases, this speed is essential to optimally treat a patient. An added advantage is that the Rotterdam system requires a much smaller amount of patient material, meaning less blood needs to be taken.
Founder of Delta Diagnostics Bart de Boar hopes to prove measurements of specific biomarkers are possible in a fraction of the time and at a significantly lower cost. The Uniiq investment should allow his company to move towards proof-of-concept.